BiotechTube

Fludarabine + Cyclophosphamide

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma, Relapsed

Conditions

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma

Trial Timeline

Mar 24, 2020 → Jun 24, 2021

NCT ID
NCT04030195

About Fludarabine + Cyclophosphamide

Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Precision BioSciences for Non-Hodgkin's Lymphoma, Relapsed. The current trial status is completed. This product is registered under clinical trial identifier NCT04030195. Target conditions include Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory.

What happened to similar drugs?

6 of 20 similar drugs in Non-Hodgkin's Lymphoma, Relapsed were approved

Approved (6) Terminated (3) Active (11)
🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3
❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3
🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3
🔄rituximab [Mabthera/Rituxan]RochePhase 3
🔄Chemotherapy (Induction Period) + RituximabRochePhase 3
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04030195Phase 1/2Completed

Competing Products

20 competing products in Non-Hodgkin's Lymphoma, Relapsed

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + Rituximab + BendamustineAbbViePhase 1
29
ABBV-291AbbViePhase 1
36
ABT-199AbbViePhase 1
29
AvelumabMerckPhase 1
33